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Non-Invasive Prenatal Diagnosis (NIPD) is a low-risk genetic test carried out on a sample of maternal blood that
screens for birth defects and inherited diseases. However, fetal cells are usually scarce in the maternal circulation. To achieve
an effective diagnosis, they need to be enriched in order to isolate a sufficient amount of them. Fetal DNA is then analyzed by
the means of various techniques, the more frequent being PCR and MPS. NIPD is being increasingly used in the early and
effective detection of monogenic diseases.
One of the most common monogenic diseases is thalassemia: a hemoglobinopathy characterized by abnormal formations of
hemoglobin. These include α-globin and β-globin mutations that result in the underproduction or even the absence of normal
globin cells. These anomalies cause a variety of symptoms that may differ from one patient to another.
• NIPD stands out as a good screening prenatal test. If the results turn to be positive, it can then be followed by invasive procedures aiming to confirm the pathology.
• Since it entails but a simple blood test, NIPD emerges as a socially welcomed test.
• Thalassemia is confirmed to be one of the most common blood disorders. There exist two different types of this disease, each one of them entailing different levels of risk. 
• Usage of NIPD in the early detection of thalassemia is still going through an experimental phase. However, numerous research projects aiming to promote and spread NIPD procedures in clinical applications are currently being conducted. 
• To develop, deepen and enhance specific scientific knowledge on NIPD: its evolution, its clinical applications, how it is and should be 
performed and the particular techniques and medical equipment usually involved in the testing process.
• To compose an accurate definition and a structured, research-based report on thalassemia, including a precise account of its types, world
presence, and observable symptoms in order to determine the most suitable ways to detect and diagnose it.
This paper is a literature review based on a guided online research in accordance with selected keywords: ‘NIPD’, ‘Non-Invasive Prenatal
Diagnosis’ and ‘thalassemia’.
Renowned medical databases were consulted (PubMed, ScienceDirect, Google Scholar) and papers were chosen according to their journal
impact.
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It is essential to have in consideration the legal framework of the country where the diagnosis is to be performed: in countries where
abortion is an illegal practice, NPID results could put pregnant women in a vulnerable, even dangerous position.
It is extremely important to provide the couples with detailed information on these procedures, their possibilities, and their limitations.
A well-trained genetic counselor who would be able to thoroughly explain the techniques, advice the couples and answer their questions
stands out as a highly-recommended option.
In order to respect the principle of autonomy, the women to be potentially tested need to be adequately informed before giving their
consent.
In order to respect the principle of justice, women should receive good medical care regardless of social, economic or ethnic reasons.
In Spain, NPID is being increasingly used in the private sector in order to detect Down’s syndrome and Edward’s syndrome.
As for the future of non-invasive prenatal testing, statistics show a tendency to implement the use of NPID in the public health sector as
well.
A widespread practice of NPID is thought to be followed by a decrease of invasive testing, resulting in a decline of miscarriage risks and
improved safety for pregnant women.
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Invasive prenatal diagnosis techniques:
Amniocentesis is a process in which amniotic fluid is 
sampled using a hollow needle inserted into the uterus.
Chorionic villus sampling (CVS) is a testing procedure 
which involves sampling the developing placenta during the 
first trimester of pregnancy in order to examine the fetal 
karyotype and/or genotype.
An accurate analysis of fetal material is crucial in order to perform
an efficient prenatal diagnosis:
• Intact fetal cells that can be found in the maternal plasma:
- Trophoblasts can be detected via the use of specific antibodies 
that are able to detect placental antigens. They usually are present 
in the maternal blood (and can therefore be isolated from it) during 
the first trimester of pregnancy only. 
- Leukocytes usually continue to circulate in the maternal blood 
long after pregnancy.
- Nucleated red blood cells (NRBC) have a short half-life. 
They present an uncommon, distinctive morphology.
• Cell-free fetal DNA (cffDNA) originates in the placenta. It 
derives from the genetic material that is released after fetal cells 
undergo apoptosis or lysis, the latter being triggered by the 
mother’s immune system. 
• Cell free fetal RNA (cffRNA) originates in active genes present 
in the placenta. It tends to appear in a smaller amount than cffDNA.
Most relevant diagnosis techniques:
 Fluorescent Immunohistochemistry (IHC) is a 
method for demonstrating the distribution of proteins in 
tissue sections. It is performed via specific antibodies that 
recognize the target protein.
 Real-time PCR combined with fluorescence testing is 
performed in order to determine whether a fetal globin chain 
is an ordinary or a mutated one.
 PCR in two steps is used when a paternal allele is 
concerned.
 MPS involves identifying single nucleotide differences in 
fractionated DNA in order to discriminate potential 
mutation points in the fetal genome.
 Real-time quantitative PCR is used to amplify, detect 
and/or quantify a targeted allele, be it a normal or a mutated 
one. Markers from paternal and maternal DNA are 
employed in the sample analysis.
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